0001104659-25-107001
SEC filingRevenue up 40% YoY to $363.9M, driven by Animal Health +55% partly from Acquisition; net income surged to $26.5M; Adjusted EBITDA margin improved to 17.0%.
Net sales for the three months ended September 30, 2025 totaled $363.9 million, a 40% increase compared to $260.4 million in the prior year period. The growth was primarily driven by the Animal Health segment, which benefited from the acquisition of Zoetis’s medicated feed additive (MFA) portfolio on October 31, 2024. Gross profit rose 43% to $119.8 million, with gross margin expanding 80 basis points to 32.9%. Excluding $1.1 million in acquisition-related cost of goods sold, gross margin was 33.2%, up 110 bps, reflecting favorable product mix and higher average selling prices, partially offset by higher input and distribution costs. Operating income increased sharply to $51.3 million from $17.7 million, as the gross profit improvement more than offset a 4% rise in SG&A expenses. SG&A included $3.8 million of insurance proceeds that partially offset higher employee-related costs. Net income reached $26.5 million compared to $7.0 million, while diluted EPS rose to $0.65 from $0.17. The effective tax rate was 26.9% versus 27.5% in the prior year.
Animal Health – Net sales grew 55% to $283.5 million, with MFAs and other up 81% (including $80.5 million from the acquired portfolio), nutritional specialties up 13%, and vaccines up 25%. Adjusted EBITDA for the segment rose 85% to $74.9 million, with margin improving to 26.4% from 22.1%.
Mineral Nutrition – Net sales increased 7% to $63.0 million due to higher demand for copper and trace minerals. Adjusted EBITDA rose 20% to $4.5 million, with margin expanding to 7.2% from 6.4%.
Performance Products – Net sales declined 7% to $17.4 million on lower demand for personal care ingredients. Adjusted EBITDA fell 30% to $1.6 million, with margin contracting to 9.2% from 12.1%.
Management does not provide explicit numerical guidance but highlights several strategic priorities: integration of the acquired MFA portfolio, ongoing defense of the Mecadox product, and investment in production capacity. The company believes its liquidity, including $192.1 million available under the revolver, is sufficient for at least the next twelve months. Risks include exposure to Israeli operations (16% of assets, 17% of net sales), potential FDA action on carbadox, and macroeconomic uncertainties including tariffs and armed conflicts. The company continues to pay a quarterly dividend of $0.12 per share.
As of September 30, 2025, Phibro held $72.8M in cash and $12.5M in short-term investments, total liquidity of $85.3M. Total debt was $743.0M, comprising $634.1M term loans (net of issuance costs $627.9M), $115M revolver draw, and $18.4M current portion. Net debt (total debt minus cash) stood at $670.2M. Stockholders' equity increased to $311.7M from $285.7M at June 30, driven by net income and OCI gains. Inventory rose to $471.8M, reflecting the Zoetis acquisition inventory step-up and ongoing stocking.
No significant purchase commitments were disclosed beyond normal operations. Environmental remediation reserves were $4.3M, unchanged from June 30. Off-balance sheet items include $2.9M in outstanding letters of credit. The 2024 Credit Agreement includes financial covenants (max net leverage 4.75x, min interest coverage 2.50x) and the company was in compliance.
During the quarter, Phibro paid $4.9M in dividends ($0.12 per share), flat YoY. No share repurchases were reported. Capital expenditures were $13.8M, slightly above prior year's $9.6M due to investment in acquired facilities. Debt activity included net revolver borrowings of $28M ($86M drawn, $58M repaid) and scheduled term loan amortization of $4.1M. The company used interest rate swaps to hedge $425M notional, fixing rates between 3.18% and 3.64% through 2030.
Animal Health remained the dominant segment with $283.5M revenue (78% of total), up 55% YoY primarily from the Zoetis acquisition (contributing $80.5M). Mineral Nutrition grew 6.6% to $63.0M, while Performance Products declined 7.4% to $17.4M. Geographically, US sales were $202.3M (56%), Latin America/Canada $87.2M, EMEA $44.9M, and Asia Pacific $29.4M. The acquisition expanded presence in Asia Pacific, which grew 101% YoY. Segment profitability is measured by Adjusted EBITDA: Animal Health $74.9M, Mineral Nutrition $4.5M, Performance Products $1.6M, totaling $81.0M, a 74% increase from $46.4M.